Trials / Completed
CompletedNCT04682106
A Study of LY3493269 in Healthy Participants
A Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an LY3493269 Formulation in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3493269 in healthy participants. The blood tests will be performed to check how much LY3493269 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3493269. The study will last up to approximately 71 days for each participant, including screening
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3493269 | Administered orally. |
| DRUG | Placebo | Administered orally. |
| DRUG | Salcaprozate Sodium | Administered orally. |
Timeline
- Start date
- 2021-05-03
- Primary completion
- 2021-11-11
- Completion
- 2021-11-11
- First posted
- 2020-12-23
- Last updated
- 2025-01-14
- Results posted
- 2025-01-14
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04682106. Inclusion in this directory is not an endorsement.